Cipla Ltd Regulatory Updates and Stock Reaction
CIPLA USFDA approvals expanded respiratory portfolio (Nintedanib for IPF); partnerships with Orchid Pharma (Cefepime-Enmetazobactam), Sanofi (CNS), Takeda (Vonoprazan).Shares fell 4% on CEO change; trading below key MAs, bearish signals. Promoter holding down 4.4% over 3 yrs.
#WatchOutFor#StockInNews#FundamentalViews
737 likes·60 comments